Copyright
©The Author(s) 2015.
World J Hepatol. May 8, 2015; 7(7): 916-921
Published online May 8, 2015. doi: 10.4254/wjh.v7.i7.916
Published online May 8, 2015. doi: 10.4254/wjh.v7.i7.916
Table 2 Suggested empirical antibiotic therapy of bacterial infections in cirrhosis
Type of infection | Community-acquired infections | Nosocomial and HCA1 infections | Local epidemiological pattern |
SBP, SBE and SB | Third generation cephalosporin | Piperacilin/tazobactam | Low prevalence of MR bacteria |
Or amoxicillin/clavulanic acid | Or carbapenem | ESBL-E | |
Plus glycopeptides (or linezolid) | MRSA and VSE (when VRE) | ||
Urinary tract infections | Third generation cephalosporin | Without sepsis: | VSE |
Or amoxicillin/clavulanic acid | Nitrofurantoin or fosfomycin | ||
With sepsis: | Low prevalence of MR bacteria | ||
Piperacilin/tazobactam | |||
Or carbapenem | ESBL-E | ||
Or plus glycopeptides (or linezolid) | MRSA and VSE (when VRE) | ||
Pneumonia | Amoxicillin/clavulanic acid | Piperacilin/tazobactam | Low prevalence of MR bacteria |
Or ceftriaxone + macrolide | Meropenem or ceftazidime + ciprofloxacin | ESBL-E and P. aeruginosa | |
Or levofloxacin | Plus vancomycin (or linezolid) | MRSA and VSE (when VRE) | |
Or moxifloxacin | |||
Skin and soft tissue infections | Amoxicillin/clavulanic acid | Meropenem or ceftazidime + oxacillin | ESBL-E and P. aeruginosa |
Or third generation cephalosporin plus oxacillin | Plus glycopeptides (or linezolid or daptomycin) | MRSA and VSE (when VRE) |
- Citation: Acevedo J. Multiresistant bacterial infections in liver cirrhosis: Clinical impact and new empirical antibiotic treatment policies. World J Hepatol 2015; 7(7): 916-921
- URL: https://www.wjgnet.com/1948-5182/full/v7/i7/916.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i7.916